Hitachi, Ltd. (TSE:6501, "Hitachi"), The University of Technology Sydney (UTS) and NTT DATA, a global leader in AI, digital business and technology services, have announced the signing of a Memorandum of Understanding to establish a strategic partnership aimed at expanding Green Transformation (GX) business in Australia. As Australia pursues a 43% reduction in CO(2) emissions […]

Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has expanded its lineup in the "Hydrolution EZY" series of air-to-water (ATW) heat pumps for the European market that utilize R290 natural refrigerant. New models with capacities of 10kW and 14kW have been added to the two existing

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA AND THE UNITED KINGDOM ONLY AND IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA), OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION

TURKU, FI / ACCESS Newswire / March 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Juho Jalkanen, CEO of the Company, subscribed 23,656 ordinary shares in Faron at price of EUR 0.5 per share on 17 March 2026, pursuant to the rights issue announced

TURKU, FI / ACCESS Newswire / March 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Yrjö Wichmann, other senior manager of the Company, acquired 10,000 ordinary shares in Faron at price of EUR 0.51942 per share on 17 March 2026. Further details are set

TURKU, FI / ACCESS Newswire / March 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Pacta sunt servanda Oy, an entity wholly owned by Vesa Karvonen, General Counsel of the Company, subscribed 72,000 ordinary shares in Faron at price of EUR 0.5 per share

STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer’s disease and pain, today announced that The company’s presentation at the international Alzheimer’s conference AD/PD 2026 is now available in full on the company’s

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinoma Study start

DENSO CORPORATION (hereinafter "DENSO") announced it has invested in Next Core Technologies, Inc. (Headquarters: Uji City, Kyoto Prefecture; President: Yuki Yamamoto; hereinafter "NCT") with the aim of jointly developing in the field of motor cores(1). These cores utilize iron-based amorphous alloys(2), which are a key materials for strengthening the competitiveness of next-generation Motor Generators (hereinafter

GENEVAD, SE / ACCESS Newswire / March 19, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company’s shares. Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF